NeuroSense Therapeutics Ltd. has announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD phase 2 clinical trial evaluating PrimeC for Alzheimer’s disease (AD).
Using NeuroKaire’s proprietary technology to generate brain cells from each patient’s blood, analysis of samples from clinically characterized AD patients demonstrated that: PrimeC treatment enhanced neuroplasticity, a key feature in supporting brain health and function and underlying memory formation and retention; and no treatment-related toxicity was observed, demonstrating the safety of PrimeC combination.
NeuroSense’s RoAD study is a randomised, double-blind, placebo-controlled phase 2 trial enrolling mild-to-moderate AD patients, designed to evaluate safety, efficacy, and biological activity of PrimeC over 12 months.
These results provide an early, patient-specific view of how PrimeC may affect disease-relevant human neurons, reinforcing the programme’s mechanistic rationale and guiding precision development in AD.
NeuroKaire’s technology reprogrammes blood sample cells into induced pluripotent stem cells (iPSCs) and differentiates them into mature human cortical neurons. After validation, neurons are exposed to PrimeC, and advanced high-content imaging using AI-driven analytics quantifies key features of neuronal structure. This generates composite response profiles tied to neuroplasticity, connectivity, and cell health.
Alon Ben-Noon, CEO of NeuroSense, said: “This is exactly the kind of early, decision-enabling signal RoAD was designed to uncover. By integrating NeuroKaire’s patient-derived neuron platform with our clinical programme, we observed measurable gains in brain-cell connectivity and a favourable safety profile. These findings strengthen PrimeC’s mechanistic rationale in Alzheimer’s and enable us to focus development with greater precision.”
Daphna Laifenfeld, CSO of NeuroKaire, said: “Our platform is designed to detect subtle, disease-relevant changes in human neurons with the sensitivity modern drug development requires. This collaboration demonstrates how a bench-to-clinic 360° workflow can transform a simple blood draw into actionable, patient-specific insights, accelerating innovation for people living with AD.”
The results will be presented at the CNS Summit 2025 in Boston in November by David Pattison, VP business development at NeuroKaire.
NeuroSense and NeuroKaire will continue evaluating PrimeC’s cellular effects in parallel with clinical outcomes from the RoAD trial, with top-line data expected following study completion.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
